AI Article Synopsis
- Rituximab is a chimeric monoclonal antibody used primarily for treating certain cancers and autoimmune diseases, but can cause rare skin reactions like leukocytoclastic vasculitis (LCV).
- Physicians must be cautious of LCV as a potential side effect following rituximab treatment, which may happen even weeks after administration.
- A case study highlights a patient with low-grade orbital B-cell lymphoma who developed LCV after weekly rituximab treatment, and resolution was achieved by stopping the drug and starting oral methylprednisolone.
Article Abstract
Rituximab is an anti-CD20 chimeric murine/human mAb mainly used to treat certain types of lymphoproliferative malignancies and autoimmune diseases. Although it has been used in the treatment of vasculitis in recent years, it rarely triggers severe vascular skin reactions such as leukocytoclastic vasculitis (LCV). Physicians should be aware of this rare adverse event that requires discontinuation of rituximab, which can occur days or even weeks after rituximab treatment. Here, we report a case of LCV observed in a patient with low-grade orbital B-cell lymphoma treated with weekly rituximab and local radiotherapy. In our case, discontinuation of rituximab and initiation of oral methylprednisolone therapy were sufficient to achieve complete resolution of the LCV.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1097/CAD.0000000000001638 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Off-label use of biologics in urticarial vasculitis: a European retrospective cohort study.
Rheumatology (Oxford)
January 2025
Department of internal medicine, CHU Cochin, AP-HP, Paris Cité University, Paris, F-75006, France.
Objectives: Urticarial vasculitis (UV) is characterized by atypical urticarial lesions and leukocytoclastic vasculitis, sometimes with extracutaneous manifestations. First-line treatment is based on colchicine, hydroxychloroquine, dapsone or low-dose glucocorticoids. In refractory forms, the use of biologics has been anecdotally described as potentially effective.
View Article and Find Full Text PDFSevere verrucous erythema elevatum diutinum responding to a combined therapy with low-dose dapsone and prednisone.
Clin Exp Dermatol
January 2025
Dermatology department, Dupuytren 2 University Hospital, Limoges, France.
A Case of Skin Limited IgA Vasculitis in an 84-Year-Old Female.
S D Med
October 2024
Transitional Year Residency Program, University of South Dakota Sanford School of Medicine, Sioux Falls, South Dakota.
IgA vasculitis is a small vessel vasculitis and while it represents the most common form of vasculitis in pediatric populations, it is rare in adults. This manuscript describes a case of skin limited IgA vasculitis in an 84-yearold Caucasian female. The patient presented for bilateral lower extremity rash that occurred roughly one month following a viral upper respiratory illness.
View Article and Find Full Text PDFMalar leukocytoclastic vasculitis in systemic lupus erythematosus.
Clin Rheumatol
January 2025
Department of Rheumatic Diseases, Tokyo Metropolitan Tama Medical Center, 2-8-29 Musashidai, Fuchu, Tokyo, 183-8524, Japan.
Treatment of exposed tibial bone by old school burr holes - a case report.
Acta Chir Plast
January 2025
Background: We report a successful wound treatment of a chronic ulcer with bone exposure using a somehow forgotten technique of creating burr holes into the bone. Most clinics would promote flap surgery to cover wounds with bone exposure, however, in some cases invasive surgery is not mandatory. We bring up an alternative treatment for such cases.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!